Atlas Venture Life Science Advisors LLC Cuts Holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO)

Atlas Venture Life Science Advisors LLC trimmed its holdings in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 64.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 992,912 shares of the company’s stock after selling 1,766,432 shares during the period. Xilio Therapeutics comprises 0.1% of Atlas Venture Life Science Advisors LLC’s investment portfolio, making the stock its 15th biggest holding. Atlas Venture Life Science Advisors LLC owned approximately 2.69% of Xilio Therapeutics worth $1,072,000 as of its most recent SEC filing.

Separately, PFG Investments LLC purchased a new position in Xilio Therapeutics in the 1st quarter valued at approximately $32,000. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Stock Up 4.1 %

NASDAQ XLO traded up $0.04 during mid-day trading on Thursday, hitting $1.00. The stock had a trading volume of 150,211 shares, compared to its average volume of 748,407. Xilio Therapeutics, Inc. has a 52-week low of $0.49 and a 52-week high of $2.94. The company has a market cap of $36.91 million, a price-to-earnings ratio of -0.39 and a beta of -0.09. The company has a 50 day simple moving average of $1.03 and a 200 day simple moving average of $0.89.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.29). As a group, equities analysts anticipate that Xilio Therapeutics, Inc. will post -1.48 earnings per share for the current fiscal year.

Xilio Therapeutics Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.